ARID3A Antibody

1. Data indicate ARID3a(+) B cells as a type of effector B cell, and link ARID3a expression in B lymphocytes to interferon alpha (IFNa)-associated inflammatory responses in systemic lupus erythematosus (SLE). PMID: 27522115
2. results suggest that appropriate regulation of ARID3a is critical for normal development of both myeloid and B lineage pathways. PMID: 26685208
3. These data reveal new functions for ARID3a in early hematopoiesis and suggest that knowledge regarding ARID3a levels in HSPCs could be informative for applications requiring transplantation of those cells. PMID: 25535283
4. Systemic lupus erythematosus (SLE) patients had increased ARID3a+ B cells compared to healthy controls. ARID3a was not expressed in naive B cells of controls, but was abundant in SLE patients. Number of ARID3a+ B cells correlated with disease activity. PMID: 25185498
5. miR-125b can act as an oncogene in B-cell acute lymphoblastic leukemia by targeting ARID3a and mediating its repression. PMID: 22469780
6. These findings support the hypothesis that Epstein-Barr virus EBNA1 initiates transcription at the C promoter via interactions between multiple EBNA1 homodimers and cellular transcription such as E2F1, ARID3A and Oct-2. PMID: 22302879
7. These results indicate both cooperative and interdependent roles for ARID3A and p53 in the transcriptional activation of p21(WAF1) in response to DNA damage. PMID: 22172947
8. functions as a critical antagonist to the p16(INK4A)-Rb tumor suppressor machinery by regulating promyelocytic leukemia protein stability PMID: 22010578
9. report that E2FBP1 inhibits accumulation of ICP0 RNA and, at the same time, is degraded via ICP0's herpes ubiquitin ligase 2 (HUL-2) activity upon HSV-1 infection. PMID: 21248039
10. Bright/ARID3a inhibition causes increased developmental plasticity in mouse and human cells. PMID: 20680960
11. Solution NMR structure of the ARID domain of human ARID3A. PMID: 20455271
12. Results show that DRIL1 disrupts cellular protection against RAS(V12)-induced proliferation downstream of the p19(ARF)/p53 pathway. PMID: 11812999
13. role in p53 regulatory pathway.(E2FBP1) PMID: 12136662
14. Variations in Bright binding and matrix attachment region activity contribute to localized control of accessibility and therefore nonrandom gene use during V(D)J recombination. PMID: 12193717
15. a putative p53-binding site was found, which specifically responded to p53, in the second intron of the E2FBP1/DRIL1 gene PMID: 12692263
16. E2FBP1 modulates cell growth through down-regulation of promyelocytic leukemia bodies. PMID: 15017387
17. Bright is not expressed in all human B lymphocyte subpopulations. PMID: 15203319
18. TFII-I directly interacts with Bright through amino acids in Bright's protein interaction domain PMID: 16738337
19. identify Bright as a contributor to accessibility of the IgH enhancer PMID: 17386101
20. Id1 inhibited DNA binding by Dril1, and the two proteins co-localized in vitro and in vivo, providing a potential mechanism for suppression of fibrosis by Id1 through inhibition of the profibrotic function of Dril1. PMID: 18583319
21. A palmitoylated pool of Bright is diverted to lipid rafts of resting B cells where it associates with signalosome components. PMID: 19214191

Show More

Hide All

HGNC: 3031

OMIM: 603265

KEGG: hsa:1820

STRING: 9606.ENSP00000263620

UniGene: Hs.501296